Dr. Rugo on VEGF-A as an Avastin Response Predictor

Hope S. Rugo, MD
Published: Friday, Sep 16, 2011

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).

A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).

A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x